ATHOS-3

Angiotensin II for the Treatment of High-Output Shock

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 321 patients with catecholamine-resistant vasodilatory shock, synthetic angiotensin II improved MAP response at 3 hours compared with placebo, without proven mortality benefit.

321

Schéma

Double-blind RCT

Critère

MAP response (≥10 mm Hg or ≥75 mm Hg) at 3 hours

Pertinence

Résultat69.9% vs 23.4% (OR 7.95; p<0.001). 28-d mortality 46% vs 54% (HR 0.78; p=0.12).

Khanna A, et al. N Engl J Med. 2017;377(5):419-430. 10.1056/NEJMoa1704154

Discussion et critique

FDA-approved 2017 for catecholamine-resistant shock; reserve for refractory cases at experienced centres.